Does IMRN pay dividends?

Immuron Ltd ADR (IMRN) does not currently pay a regular dividend.

What is IMRN's market cap?

Immuron Ltd ADR (IMRN) has a market capitalization of $9.28M with a current stock price of $1.11.

Immuron Ltd ADR (IMRN)

Official site

HEALTHCARE • BIOTECHNOLOGY • NASDAQ

$1.11

-0.04 (-3.48%)

Market Cap: $9.28M

Last updated: Sep 01, 2026 at 5:00 PM ET

Earnings

Performance (10Y)

Beat Rate

67%(4/6)

Avg Surprise

-729.45%

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Jun 30, 2026Jun 26 Reported Aug 27, 2026Reported Aug 27	$N/A	N/A	-	N/A	Beat	1	No revisions (30d)	-
Dec 31, 2025Dec 25 Reported Feb 25, 2026Reported Feb 25	$-0.20	$-0.01	-	-2586.23%	Miss	-	-	-1891.0%
Sep 30, 2025Sep 25 Reported Dec 3, 2025Reported Dec 3	$0.00	$0.00	-	N/A	Beat	-	-	+100.0%
Jun 30, 2025Jun 25 Reported Aug 28, 2025Reported Aug 28	$-0.01	$0.00	-	N/A	Miss	1	-	-
Mar 31, 2025Mar 25 Reported May 28, 2025Reported May 28	$0.00	$0.00	-	N/A	Beat	-	-	-
Dec 31, 2024Dec 24 Reported Feb 28, 2025Reported Feb 28	$-0.01	$0.00	$0.00 - $0.00	N/A	Miss	0	No revisions (30d)	-
Dec 30, 2024Dec 24 Reported Feb 28, 2025Reported Feb 28	$-0.27	$-0.01	-	-1941.49%	Miss	-	-	-
Sep 30, 2024Sep 24 Reported Oct 16, 2024Reported Oct 16	$0.00	$0.00	$0.00 - $0.00	N/A	Beat	0	No revisions (30d)	+100.0%
Jun 30, 2024Jun 24 Reported Aug 29, 2024Reported Aug 29	$0.00	$0.00	$0.00 - $0.00	N/A	Beat	0	No revisions (30d)	-
Mar 31, 2024Mar 24 Reported Apr 29, 2024Reported Apr 29	$0.00	$0.00	-	N/A	Beat	-	-	-
Dec 31, 2023Dec 23 Reported Feb 27, 2024Reported Feb 27	$0.00	$0.00	-	N/A	Beat	-	-	-
Dec 30, 2023Dec 23 Reported Feb 28, 2024Reported Feb 28	$-0.25	N/A	-	N/A	Beat	-	-	-
Sep 30, 2023Sep 23 Reported Oct 11, 2023Reported Oct 11	$0.00	$0.00	-	N/A	Beat	-	-	+100.0%
Jun 30, 2023Jun 23 Reported Aug 30, 2023Reported Aug 30	$0.00	$0.00	-	N/A	Beat	-	-	-
Mar 31, 2023Mar 23 Reported Apr 5, 2023Reported Apr 5	$0.00	$0.00	-	N/A	Beat	-	-	-
Dec 31, 2022Dec 22 Reported Mar 1, 2023Reported Mar 1	$0.00	$0.00	-	N/A	Beat	-	-	-
Dec 30, 2022Dec 22 Reported Feb 28, 2023Reported Feb 28	$-0.12	N/A	-	N/A	Beat	-	-	-
Sep 30, 2022Sep 22 Reported Nov 30, 2022Reported Nov 30	$0.00	$0.00	-	N/A	Beat	-	-	+100.0%
Jun 30, 2022Jun 22 Reported Aug 30, 2022Reported Aug 30	$0.00	$0.00	-	N/A	Beat	-	-	-
Mar 31, 2022Mar 22 Reported Jun 1, 2022Reported Jun 1	$0.00	$0.00	-	N/A	Beat	-	-	-
Dec 31, 2021Dec 21 Reported Feb 25, 2022Reported Feb 25	$0.00	$0.00	-	N/A	Beat	-	-	+100.0%
Dec 30, 2021Dec 21 Reported Feb 25, 2022Reported Feb 25	$-0.23	N/A	-	N/A	Beat	-	-	-5053.3%
Sep 30, 2021Sep 21 Reported Dec 1, 2021Reported Dec 1	$0.00	$0.00	-	N/A	Beat	-	-	+100.0%
Jun 30, 2021Jun 21 Reported Sep 7, 2021Reported Sep 7	$0.00	$0.00	-	N/A	Beat	-	-	+100.0%
Mar 31, 2021Mar 21 Reported Jun 2, 2021Reported Jun 2	$-0.00	$0.00	-	N/A	Miss	-	-	+53.2%
Dec 31, 2020Dec 20 Reported Feb 25, 2021Reported Feb 25	$-0.00	$0.00	-	N/A	Miss	-	-	-66.7%
Dec 30, 2020Dec 20 Reported Dec 30, 2020Reported Dec 30	$-0.80	N/A	-	N/A	Beat	-	-	-33425.0%
Sep 30, 2020Sep 20 Reported Dec 2, 2020Reported Dec 2	$-0.01	$0.00	-	N/A	Miss	-	-	+95.9%
Jun 30, 2020Jun 20 Reported Aug 30, 2020Reported Aug 30	$-0.01	$0.00	-	N/A	Miss	-	-	-213.3%
Mar 31, 2020Mar 20 Reported Apr 20, 2020Reported Apr 20	$-0.00	$0.00	-	N/A	Miss	-	-	+6.9%
Dec 31, 2019Dec 19 Reported Feb 26, 2020Reported Feb 26	$-0.00	$0.00	-	N/A	Miss	-	-	+65.7%
Dec 30, 2019Dec 19 Reported Dec 30, 2019Reported Dec 30	$-0.24	N/A	-	N/A	Beat	-	-	-3335.2%
Sep 30, 2019Sep 19 Reported Oct 14, 2019Reported Oct 14	$-0.00	$0.00	-	N/A	Miss	-	-	+99.1%
Jun 30, 2019Jun 19 Reported Aug 30, 2019Reported Aug 30	$-0.00	N/A	-	+85.50%	Beat	-	-	+29.3%
Mar 31, 2019Mar 19 Reported Apr 15, 2019Reported Apr 15	$-0.01	$0.00	-	N/A	Miss	-	-	+98.8%
Dec 31, 2018Dec 18 Reported Feb 26, 2019Reported Feb 26	$-0.01	N/A	-	+64.50%	Beat	-	-	+98.8%
Dec 30, 2018Dec 18 Reported Dec 30, 2018Reported Dec 30	$-0.33	N/A	-	N/A	Beat	-	-	+47.5%
Sep 30, 2018Sep 18 Reported Nov 28, 2018Reported Nov 28	$-0.00	$0.00	-	N/A	Miss	-	-	+99.1%
Jun 30, 2018Jun 18 Reported Aug 29, 2018Reported Aug 29	$-0.59	$-0.59	-	+0.00%	Beat	-	-	+5.2%
Mar 31, 2018Mar 18 Reported May 30, 2018Reported May 30	$-0.59	$-0.60	-	+1.03%	Beat	-	-	+5.2%
Dec 31, 2017Dec 17 Reported Feb 27, 2018Reported Feb 27	$-0.62	$0.00	-	N/A	Miss	-	-	+39.0%
Dec 30, 2017Dec 17 Reported Dec 30, 2017Reported Dec 30	$-0.45	N/A	-	N/A	Beat	-	-	+52.9%
Sep 30, 2017Sep 17 Reported Nov 29, 2017Reported Nov 29	$-0.62	$0.00	-	N/A	Miss	-	-	-
Jun 30, 2017Jun 17 Reported Sep 28, 2017Reported Sep 28	$-0.63	$0.00	-	N/A	Miss	-	-	-
Dec 31, 2016Dec 16 Reported Feb 28, 2017Reported Feb 28	$-1.02	$0.00	-	N/A	Miss	-	-	-
Dec 30, 2016Dec 16 Reported Dec 30, 2016Reported Dec 30	$-0.95	N/A	-	N/A	Beat	-	-	-

Key Metrics

Valuation
P/E Ratio	-2.26	EV/EBITDA	0.77x
Price/FCF	N/A	FCF Yield	N/A
Profitability
Profit Margin	-49.80%	Operating Margin	-57.70%
ROE	-40.30%	ROIC	N/A
Financial Health
Debt/Equity	N/A	Interest Coverage	N/A
Current Ratio	7.17x	Quick Ratio	5.90x
Trading Statistics
Beta	0.51	Avg Volume	16.20K
52-Week High	$2.39	52-Week Low	$0.68

Technical Indicators Dashboard

Moving Averages

SMA 10$1.15

SMA 20$1.12

SMA 50$1.13

SMA 200$1.03

EMA 10$1.13

EMA 20$1.13

EMA 50$1.12

EMA 200$1.16

MACD

Line: 0.00Signal: 0.00Hist: 0.00

ADX

ADX: 13.0+DI: 20.0-DI: 16.8

Aroon & PSAR

Aroon Up68.0

Aroon Down36.0

PSAR$1.11

Bollinger Bands

Upper Band$1.19

Lower Band$1.04

%B Position1343%(Upper)

Band Width0.44

RSI (14-Day)

Neutral

47.6

Momentum Oscillators

Stoch %K58.8

Stoch %D62.4

Williams %R-57.9

ROC (10d)2.8%

Momentum0.03

CCI (20d)9.1

MFI (14d)57.0

Volatility Measures

ATR (14d)$0.07(6.0%)

StdDev (20d)0.04

Hist Vol52.7%(High)

Volume Flow

VWAP$1.12

OBV-8.5M

AD Line7.9M

CMF (20d)-0.061

Volume Metrics

Avg Vol (20d)14.8K

Vol Ratio1.5x

VWMA (20d)$1.13

Pivot Points

R3$1.20

R2$1.19

R1$1.17

Pivot Point$1.16

S1$1.14

S2$1.13

S3$1.11

Advanced Oscillators

TSI1.82

Ultimate Osc36.9

KST11.41

Financial Data

Quarter	Jun 2026	Dec 2025	Jun 2025	Mar 2025	Dec 2024	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Dec 2023	Sep 2023
Total Revenue	$3.58M	$4.11M	$3.29M	$1.65M	$3.99M	$3.99M	$2.00M	$2.55M	$1.27M	$2.36M	$2.36M	$1.18M
Cost of Revenue	$1.22M	$1.50M	$1.18M	$592,306	$1.34M	$1.34M	$668,646	$790,836	$395,418	$775,232	$775,232	$387,616
Gross Profit	$2.35M	$2.60M	$2.11M	$1.05M	$2.66M	$2.66M	$1.33M	$1.76M	$878,225	$1.58M	$1.58M	$790,174

Operating Expenses	$4.82M	$4.87M	$4.95M	$2.46M	$5.20M	$5.20M	$2.60M	$5.54M	$2.77M	$3.60M	$3.60M	$1.80M
R&D	$0	$1.16M	$1.62M	$807,579	$1.98M	$1.98M	$991,069	$2.72M	$1.36M	$2.65M	$2.65M	$1.33M
SG&A	$0	$0	$2.23M	$1.11M	$2.26M	$3.86M	$1.13M	$2.61M	$1.30M	$1.95M	$2.68M	$974,615
Operating Income	$-2,462,462	$-2,264,948	$-2,842,978	$-1,402,878	$-2,538,792	$-2,538,792	$-1,269,396	$-3,781,090	$-1,890,545	$-2,020,028	$-2,020,028	$-1,010,014

Interest Income	$0	$0	$0	$0	$0	$49,972	$0	$0	$0	$0	$153,508	$0
Interest Expense	$8,242	$6,463	$0	$0	$0	$2,657	$3,569	$3,569	$541,343	$4,007	$4,007	$26,577
Income Before Tax	$-2,145,785	$-2,303,334	$-2,764,390	$-1,363,584	$-2,488,820	$-2,488,820	$-1,244,410	$-4,863,776	$-2,431,888	$-2,073,182	$-2,073,182	$-1,036,591
Income Tax Expense	$-199,068	$-419,472	$0	$0	$0	$0	$-1,253,365	$-545,372	$0	$-219,609	$0	$0

Net Income	$-1,946,717	$-1,883,860	$-2,764,390	$-1,363,584	$-2,488,820	$-2,488,820	$-1,244,410	$-4,863,776	$-2,431,888	$-2,073,182	$-2,073,182	$-1,036,591

EBITDA	$-2,462,462	$-2,296,871	$-2,852,204	$-1,397,475	$-2,535,834	$-2,535,834	$-1,267,917	$-3,358,009	$-1,585,740	$-2,016,360	$-2,016,360	$-1,008,180
EBIT	N/A	N/A	$-2,855,162	$-1,408,970	$-2,538,792	$-2,538,792	$-1,269,396	$-3,361,322	$-1,597,906	$-2,020,028	$-2,020,028	$-1,010,014

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about IMRN

News

Immuron Limited Reports 5.9% Revenue Rise and Reduced Full-Year Loss in Appendix 4E

Immuron Limited (ASX:IMC) announced a 5.9% increase in revenue to $7,713,601 for the year ended June 30, 2026, primarily driven by Travelan® sales in Australia and North America. The company also significantly reduced its net loss after tax by 26.4% to $3,838,699. Immuron's cash and cash equivalents substantially increased to $9,017,814, and audited financial statements are expected by September 30, 2026.

Kalkine•Aug 28, 2026 9:15 AM8/28/26•

Bullish

Immuron Reports 6% Rise in FY26 Global Sales to $7.7 Million with Improved Net Loss

Immuron (ASX:IMC) announced its preliminary financial results for fiscal year 2026, reporting a 6% increase in global sales revenue to $7.7 million. The company also saw an improved net loss of $3.8 million, a $1.4 million reduction from the previous year. Immuron achieved key operational milestones, including FDA approval for IMM-529 and completing a large-scale Travelan trial, while maintaining strong cash reserves to fund future operations.

Kalkine Media•Aug 28, 2026 9:15 AM8/28/26•

Somewhat-Bullish

Immuron (IMRN) lifts FY26 sales as it shifts to partner-funded drug development

Immuron Ltd (IMRN) reported a 6% increase in global sales revenue to A$7.7 million for FY2026, driven by strong performance in Australia and the U.S. The company is strategically repositioning itself as a commercially focused biopharmaceutical business, relying on over-the-counter products like Travelan and ProIBS, while seeking partners to fund the development and commercialization of its clinical assets IMM-124E and IMM-529. This shift aims to reduce R&D expenditure and cash burn, leveraging upfront fees, milestones, and royalties from licensing agreements.

Stock Titan•Aug 19, 2026 10:11 AM8/19/26•

Somewhat-Bullish

Immuron CEO Steven Lydeamore to Present at Emerging Growth Conference

Immuron Limited's CEO, Steven Lydeamore, is scheduled to present at the Emerging Growth Conference on August 19, 2026, from 4:25pm to 4:35pm U.S. Eastern Time. The Australian biopharmaceutical company, dual-listed on ASX (IMC) and NASDAQ (IMRN), specializes in developing orally delivered targeted polyclonal antibodies for infectious diseases. Immuron's product portfolio includes Travelan® for Travelers' Diarrhea, IMM-529 for Clostridioides difficile infection, and ProIBS® for IBS symptoms.

Kalkine•Aug 18, 2026 11:40 PM8/18/26•

Somewhat-Bullish

Immuron Limited (NASDAQ: IMRN) highlights antibody platform and CEO talk at Emerging Growth Conference

Immuron Limited announced that CEO Steven Lydeamore will present virtually at the Emerging Growth Conference on August 19, 2026. The company highlighted its orally delivered targeted polyclonal antibody platform, featuring its lead product Travelan® for travelers' diarrhea, pipeline asset IMM-529 for C. difficile infection, and the distribution of ProIBS® for IBS symptoms. The presentation will cover Immuron's proprietary technology based on hyper-immune bovine colostrum-derived immunoglobulins and its applications.

Stock Titan•Aug 13, 2026 9:42 AM8/13/26•

Somewhat-Bullish

Frequently Asked Questions About IMRN

Does IMRN pay dividends?: Immuron Ltd ADR (IMRN) does not currently pay a regular dividend.
What is IMRN's market cap?: Immuron Ltd ADR (IMRN) has a market capitalization of $9.28M with a current stock price of $1.11.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In